DMAC (DiaMedica Therapeutics) Cash Flow for Lease Financing: $ Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DMAC DiaMedica Therapeutics Inc DMAC
31 GF Score
Price $7.69
! 2 Warning Signs
View Full Analysis

What is DiaMedica Therapeutics Cash Flow for Lease Financing?

DiaMedica Therapeutics DMAC +5.96% 31 Cash Flow for Lease Financing is $ Mil as of Jun. 2026. GuruFocus rates DMAC with a GF Score™ of 31/100. The stock has 2 warning signs investors should review.

DiaMedica Therapeutics's Cash Flow for Lease Financing for the three months ended in Jun. 2026 was $ Mil. DiaMedica Therapeutics's Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Jun. 2026 was $ Mil.

Compared with last quarter ($ Mil in Mar. 2026 ), DiaMedica Therapeutics's Cash Flow for Lease Financing remained the same in Jun. 2026 ($ Mil).

DiaMedica Therapeutics Cash Flow for Lease Financing Historical Data

* Premium members only.

The historical data trend for DiaMedica Therapeutics's Cash Flow for Lease Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DiaMedica Therapeutics Cash Flow for Lease Financing Chart

DiaMedica Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Flow for Lease Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

DiaMedica Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cash Flow for Lease Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -
DMAC
31GF Score
DiaMedica Therapeutics Inc DMAC
Cash Flow for Lease Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DiaMedica Therapeutics Cash Flow for Lease Financing Calculation

Cash Flow for Lease Financing is change in cash flow resulting from increase or decrease in lease financing.


Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $ Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow for Lease Financing of $ Mil mean?
DiaMedica Therapeutics (DMAC) has a Cash Flow for Lease Financing of $ Mil as of Jun. 2026. Cash Flow for Lease Financing is change in cash flow resulting from increase or decrease in lease financing. View historical data on DiaMedica Therapeutics and its competitors.
Is DiaMedica Therapeutics' Cash Flow for Lease Financing too high?
DiaMedica Therapeutics' current Cash Flow for Lease Financing is $ Mil. Overall, DiaMedica Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does DiaMedica Therapeutics' Cash Flow for Lease Financing compare to SABS and AGEN?
DiaMedica Therapeutics' Cash Flow for Lease Financing of $ Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Lease Financing for a Biotechnology company?
A good Cash Flow for Lease Financing depends on the Biotechnology industry context. However, Cash Flow for Lease Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Lease Financing mean?
A high Cash Flow for Lease Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow for Lease Financing is change in cash flow resulting from increase or decrease in lease financing. View historical data on DiaMedica Therapeutics and its competitors. DiaMedica Therapeutics's current Cash Flow for Lease Financing is $ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DiaMedica Therapeutics stock overvalued right now?
DiaMedica Therapeutics (DMAC) has a current Cash Flow for Lease Financing of $ Mil. The current Cash Flow for Lease Financing is $ Mil. DiaMedica Therapeutics' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Lease Financing calculated?
Cash Flow for Lease Financing is calculated from a company's financial statements. For DiaMedica Therapeutics (DMAC), the current Cash Flow for Lease Financing is $ Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

DiaMedica Therapeutics Business Description

Address 301 Carlson Parkway, Suite 210, Minneapolis, MN, USA, 55305
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company based in the United States that develops treatments for ischemic and inflammatory diseases. Its lead product candidate, DM199 (rinvecalinase alfa), is a recombinant form of human tissue kallikrein-1, a protease enzyme that regulates blood flow and inflammation; it is being developed for acute ischemic stroke and preeclampsia. The company's earlier-stage pipeline includes DM300, a recombinant human ulinastatin, a broad-spectrum serine protease inhibitor being explored as a potential therapy for severe acute pancreatitis. DiaMedica does not yet market approved products and generates no product revenue, funding its research and clinical development through equity financings and other capital-raising activities. Its activities are centered on conducting clinical trials in the United States and other jurisdictions, with a focus on addressing conditions that have limited or no approved treatment options.
31GF Score

Get the complete analysis for DMAC

Cash Flow for Lease Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.69
Price